Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

3 Healthcare Dividend Stocks To Buy

By MarketBeat.com (Sean Sechler )Stock MarketsOct 28, 2020 07:47AM ET
www.investing.com/analysis/3-healthcare-dividend-stocks-to-buy-200542669
3 Healthcare Dividend Stocks To Buy
By MarketBeat.com (Sean Sechler )   |  Oct 28, 2020 07:47AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Adding dividend-paying stocks in a strong industry is one of the best ways to boost your overall returns over the years. Since healthcare is one of the most important issues impacting our country today thanks to the pandemic and the upcoming election, there are some intriguing investment opportunities in the sector to check out at this time. When you look at the big picture for the next decade, the healthcare industry should benefit from trends like technological advances, a growing middle class in emerging markets, and aging generations such as baby boomers. These trends will likely lead to increased profitability for healthcare companies and in turn, provide strong gains for your portfolio.

It’s safe to say there’s a lot to like about healthcare stocks at this time. They held up extremely well during the March selloff and offer some defensive characteristics along with growth potential. Another plus is that the best healthcare stocks feature strong balance sheets that could mean dividend increases in the future. If you are interested in adding income to your portfolio with companies that perform consistently and see steady demand for their products and services, this sector is a great option.

Keep reading below to learn about 3 healthcare dividend stocks to consider buying.

Pfizer

The first healthcare stock on our list is Pfizer (NYSE:PFE), a company that is poised to benefit from a 6% compound annual growth rate of prescription drug sales during the 2019-2024 period. It’s one of the world’s largest biopharmaceutical company with a diverse portfolio of drugs that generate steady cash flows, a strong pipeline of new drugs including 95 compounds in various clinical trial phases, and a solid dividend yield of 4% at this time. Pfizer also plans to merge its Upjohn business, which owns many of the company’s older drugs that are seeing declining sales, with a company called Mylan (NASDAQ:NASDAQ:MYL) in Q4. That should allow the company to focus more on growth.

It’s also worth noting that Pfizer could have a major bullish catalyst on the horizon. The company reported its Q3 earnings today and mentioned that nearly 36,000 people have received a second vaccination in its COVID-19 vaccine phase 2/3 clinical trial. If the vaccine is approved by the FDA in the coming months Pfizer stock is likely to rally. This is a good pick for more conservative investors that are interested in a healthcare stock with a strong dividend yield.

Cardinal Health

Another dividend-paying healthcare stock that should be on investor’s radar at this time is Cardinal Health (NYSE:CAH), a company that is a member of the S&P 500 and is one of the top 3 U.S. distributors of pharmaceuticals, medical-surgical supplies, and other healthcare products. The stock has not performed well this year but could be worth a look thanks to a strong dividend yield of 4.05% along with FY20 top-line growth of 5% year-over-year. It’s a company that has increased its annual dividend payout for more than 30 consecutive years, which tells investors that future payout increases are definitely in the realm of possibility.

COVID-19 has disrupted Cardinal Health’s business, as a large portion of the company’s revenue comes from medical, surgical, and lab products that are dependent on elective procedures. With that said, there is a very strong demand for personal protective equipment that the company produces, and many hospitals have seen elective procedures bounce back as the pandemic drags on. The stock is arguably trading at a discount and should remain an industry leader in the coming years due to high barriers of entry for competitors.

Quest Diagnostics

Quest Diagnostics is a company that provides diagnostic testing, information, and services to healthcare professionals around the world. It’s a healthcare company that is greatly benefitting from the pandemic thanks to heavy demand for COVID-19 testing, as it currently processes roughly 25% of all U.S. COVID-19 testing volumes. There’s a lot to like about the future of Quest Diagnostics, as medical technology continuously improves and could lead to more complex testing that typically provides higher profit margins for the company.

Quest’s latest earnings release was impressive, as the company reported Q3 revenue of $2.79 billion, a year-over-year increase of 42.5%. Q3 EPS for the company as up by 164.6% from 2019 as well, confirming that Quest is doing a ton of business during the pandemic. The company also raised its FY 2020 outlook, which tells us that there could be more earnings upside in store going forward. While the dividend yield of 1.8% is lower than other stocks on our list, Quest Diagnostics stock arguably has the most upside.

  • Quest Diagnostics (NYSE:DGX) Improves Its Standing After Earnings
  • The Diagnosis for Quest Diagnostics: Strong Growth Ahead

Original Post

3 Healthcare Dividend Stocks To Buy
 

Related Articles

Jani Ziedins
Why Bears Keep Getting It Wrong By Jani Ziedins - Dec 03, 2021

Surprise, surprise, the S&P 500 recovered from Wednesday’s massive intraday reversal. Okay, no one was really surprised because Thursday’s 1.4% bounce was the market’s third...

3 Healthcare Dividend Stocks To Buy

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email